

## New Paradigm of Diabetes Treatment

April 10(Fri), 09:30 ~ 12:00 / Room.318

According to a report published by International Diabetes Federation, it was estimated that over five hundred million people throughout the world have diabetes. The number of patients who are suffering from diabetes has been rapidly increased. In Korea, for example, about 3.2 million people aged 30 years or older have diabetes. In other words, 1 out of 10 people aged over 30 and 2 out of 10 people aged over 65 are suffering from diabetes. In this session, 3 leading diabetes-related companies specialized in antidiabetics, will talk about New paradigm of diabetes treatment.

- Development of long acting antidiabetic drug, SR-Exenatide PT302" by PEPTRON
- Innovative DNA medicine as therapeutics for diabetic peripheral neuropathy by VIROMED
- DME Laser therapeutics through the RPE cell regeneration by LUTRONIC

SESSION CHAIR **Nam Park**, CEO, Advanced Healthcare Asia

09:30 ~ 10:00 **Increasing of the Diabetes and Current State of Developing Therapies**  
**Nam Park**, CEO, Advanced Healthcare Asia, Hong Kong

10:00 ~ 10:30 **Development of Long Acting Antidiabetic Drug, SR-Exenatide PT302"**  
**Heeyong Lee**, Director, Business Development Department, PEPTRON, Korea

10:30 ~ 11:00 **Innovative DNA Medicine as Therapeutics for Diabetic Peripheral Neuropathy**  
**Seungshin Yu**, Director, New Business Planning Division, VIROMED, Korea

11:00 ~ 11:30 **DME Laser Therapeutics through the RPE Cell Regeneration**  
**Dominic KH Lee**, CFO, LUTRONIC, Korea

11:30 ~ 12:00 [Panel Discussion](#)